PURPOSE: This study evaluated the tolerability, pharmacokinetics, and preliminary antitumor activity of EZN-2208, a water-soluble poly(ethylene) glycol conjugate of SN38. METHODS: Patients with advanced malignancies were enrolled in dose-escalating cohorts (3 + 3 design). EZN-2208 was administered as a 1-h intravenous infusion given weekly for 3 weeks per each 4-week cycle. Doses ranged from 1 to 12 mg/m(2). RESULTS: Forty-one patients received EZN-2208. All patients had received prior cancer therapy (median = 2, range = 1-11). Twenty patients (49 %) had received prior irinotecan, and one patient had received prior topotecan. One patient in the 9-mg/m(2) cohort had dose-limiting toxicity (grade 3 febrile neutropenia), and one patient in the 12-mg/m(2) cohort had grade 3 neutropenia that resulted in the inability to deliver the third dose of EZN-2208. The most commonly reported drug-related adverse events were nausea (51 %), diarrhea (46 %), fatigue (41 %), alopecia (29 %), neutropenia (24 %), and vomiting (22 %). Administration of EZN-2208 results in prolonged exposure to SN38. Stable disease, sometimes prolonged, was observed as best response. CONCLUSIONS: EZN-2208 has an acceptable safety profile in previously treated patients with advanced malignancies. The recommended phase II dose of EZN-2208 administered according to this schedule was 9 mg/m(2).
PURPOSE: This study evaluated the tolerability, pharmacokinetics, and preliminary antitumor activity of EZN-2208, a water-soluble poly(ethylene) glycol conjugate of SN38. METHODS:Patients with advanced malignancies were enrolled in dose-escalating cohorts (3 + 3 design). EZN-2208 was administered as a 1-h intravenous infusion given weekly for 3 weeks per each 4-week cycle. Doses ranged from 1 to 12 mg/m(2). RESULTS: Forty-one patients received EZN-2208. All patients had received prior cancer therapy (median = 2, range = 1-11). Twenty patients (49 %) had received prior irinotecan, and one patient had received prior topotecan. One patient in the 9-mg/m(2) cohort had dose-limiting toxicity (grade 3 febrile neutropenia), and one patient in the 12-mg/m(2) cohort had grade 3 neutropenia that resulted in the inability to deliver the third dose of EZN-2208. The most commonly reported drug-related adverse events were nausea (51 %), diarrhea (46 %), fatigue (41 %), alopecia (29 %), neutropenia (24 %), and vomiting (22 %). Administration of EZN-2208 results in prolonged exposure to SN38. Stable disease, sometimes prolonged, was observed as best response. CONCLUSIONS:EZN-2208 has an acceptable safety profile in previously treated patients with advanced malignancies. The recommended phase II dose of EZN-2208 administered according to this schedule was 9 mg/m(2).
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: L Iyer; C D King; P F Whitington; M D Green; S K Roy; T R Tephly; B L Coffman; M J Ratain Journal: J Clin Invest Date: 1998-02-15 Impact factor: 14.808
Authors: Helen M Dodds; Peter J Tobin; Clinton F Stewart; Pam Cheshire; Suzan Hanna; Peter Houghton; Laurent P Rivory Journal: J Pharmacol Exp Ther Date: 2002-11 Impact factor: 4.030
Authors: K Takasuna; T Hagiwara; M Hirohashi; M Kato; M Nomura; E Nagai; T Yokoi; T Kamataki Journal: Cancer Res Date: 1996-08-15 Impact factor: 12.701
Authors: A Sparreboom; M J de Jonge; P de Bruijn; E Brouwer; K Nooter; W J Loos; R J van Alphen; R H Mathijssen; G Stoter; J Verweij Journal: Clin Cancer Res Date: 1998-11 Impact factor: 12.531
Authors: Woondong Jeong; Sook Ryun Park; Annamaria Rapisarda; Nicole Fer; Robert J Kinders; Alice Chen; Giovanni Melillo; Baris Turkbey; Seth M Steinberg; Peter Choyke; James H Doroshow; Shivaani Kummar Journal: Invest New Drugs Date: 2013-11-16 Impact factor: 3.850
Authors: Romain Coriat; Sandrine J Faivre; Olivier Mir; Chantal Dreyer; Stanislas Ropert; Mohammed Bouattour; Robert Desjardins; François Goldwasser; Eric Raymond Journal: Int J Nanomedicine Date: 2016-11-21
Authors: Lina Chernov; Rebecca J Deyell; Malathi Anantha; Nancy Dos Santos; Roger Gilabert-Oriol; Marcel B Bally Journal: Cancer Med Date: 2017-05-23 Impact factor: 4.452
Authors: Amanda J Stolarz; Bijay P Chhetri; Michael J Borrelli; Samir V Jenkins; Azemat Jamshidi-Parsian; Joshua H Phillips; Daniel Fologea; Jay Gandy; Robert J Griffin Journal: Int J Mol Sci Date: 2022-10-02 Impact factor: 6.208